CA2797123A1 - Ophthalmic composition - Google Patents
Ophthalmic composition Download PDFInfo
- Publication number
- CA2797123A1 CA2797123A1 CA2797123A CA2797123A CA2797123A1 CA 2797123 A1 CA2797123 A1 CA 2797123A1 CA 2797123 A CA2797123 A CA 2797123A CA 2797123 A CA2797123 A CA 2797123A CA 2797123 A1 CA2797123 A1 CA 2797123A1
- Authority
- CA
- Canada
- Prior art keywords
- ophthalmic composition
- group
- composition according
- polyester
- hyperbranched polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract 23
- 229920006150 hyperbranched polyester Polymers 0.000 claims abstract 7
- 239000002736 nonionic surfactant Substances 0.000 claims abstract 5
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims abstract 4
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims abstract 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960004605 timolol Drugs 0.000 claims abstract 4
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims abstract 3
- 239000002876 beta blocker Substances 0.000 claims abstract 3
- 229940097320 beta blocking agent Drugs 0.000 claims abstract 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract 3
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract 3
- 229920000136 polysorbate Polymers 0.000 claims abstract 3
- 229950008882 polysorbate Drugs 0.000 claims abstract 3
- 229960004324 betaxolol Drugs 0.000 claims abstract 2
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960001222 carteolol Drugs 0.000 claims abstract 2
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 claims abstract 2
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 claims abstract 2
- 229960000831 levobunolol Drugs 0.000 claims abstract 2
- 229960002704 metipranolol Drugs 0.000 claims abstract 2
- BQIPXWYNLPYNHW-UHFFFAOYSA-N metipranolol Chemical compound CC(C)NCC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BQIPXWYNLPYNHW-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960003712 propranolol Drugs 0.000 claims abstract 2
- 229920000587 hyperbranched polymer Polymers 0.000 claims 9
- 125000005313 fatty acid group Chemical group 0.000 claims 4
- 125000000524 functional group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 229920000728 polyester Polymers 0.000 claims 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims 2
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 claims 2
- 229960000722 brinzolamide Drugs 0.000 claims 2
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical group CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 claims 2
- 229960003933 dorzolamide Drugs 0.000 claims 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 229920002873 Polyethylenimine Polymers 0.000 claims 1
- -1 Polypropylenimine Polymers 0.000 claims 1
- 229960000571 acetazolamide Drugs 0.000 claims 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 206010015946 Eye irritation Diseases 0.000 abstract 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 231100000013 eye irritation Toxicity 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/774,419 US8211450B2 (en) | 2010-05-05 | 2010-05-05 | Ophthalmic composition |
| US12/774,419 | 2010-05-05 | ||
| PCT/US2011/035147 WO2011140194A1 (en) | 2010-05-05 | 2011-05-04 | Ophthalmic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2797123A1 true CA2797123A1 (en) | 2011-11-10 |
Family
ID=44902332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2797123A Abandoned CA2797123A1 (en) | 2010-05-05 | 2011-05-04 | Ophthalmic composition |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8211450B2 (enExample) |
| EP (1) | EP2566487A4 (enExample) |
| JP (1) | JP2013528589A (enExample) |
| KR (1) | KR20130121685A (enExample) |
| CN (1) | CN103096901A (enExample) |
| CA (1) | CA2797123A1 (enExample) |
| MX (1) | MX2012012846A (enExample) |
| WO (1) | WO2011140194A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013001116A (es) * | 2010-07-29 | 2013-06-05 | Santen Pharma Co Ltd | Cuerpo para soporte de farmaco, y metodo para producir el mismo. |
| WO2013114397A2 (en) * | 2012-01-16 | 2013-08-08 | Biocon Limited | Pharmaceutically acceptable salt of brinzolamide and composition thereof |
| US9820991B2 (en) * | 2013-11-08 | 2017-11-21 | Sentiss Pharma Private Limited | Pharmaceutical composition comprising brinzolamide |
| CN103740831B (zh) * | 2014-01-13 | 2015-01-28 | 宁波海尔施基因科技有限公司 | 一种指导β-受体阻断药用药的引物组合物、多重基因检测试剂盒及其使用方法 |
| ES2838756T3 (es) * | 2014-01-24 | 2021-07-02 | Sentiss Pharma Private Ltd | Composición farmacéutica que comprende brinzolamida |
| CN110483233B (zh) | 2014-05-16 | 2022-06-14 | 西方化学股份有限公司 | 制备1,1,3,3-四氯丙烯的方法 |
| CN106535943A (zh) * | 2014-07-11 | 2017-03-22 | 富士胶片株式会社 | 眼科用水性组合物 |
| WO2016022066A1 (en) | 2014-08-04 | 2016-02-11 | Jerry Tan Eye Surgery Pte Ltd | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting |
| KR101773669B1 (ko) | 2015-07-30 | 2017-08-31 | 포항공과대학교 산학협력단 | 생체적합성 각막세포 전구체 분화방법 및 각막세포 전구체 조성물 |
| JP6050454B1 (ja) * | 2015-09-28 | 2016-12-21 | 参天製薬株式会社 | 水性医薬組成物 |
| JP6178028B1 (ja) * | 2016-03-14 | 2017-08-09 | 参天製薬株式会社 | ドルゾラミドとチモロールと界面活性剤を含有する医薬組成物 |
| AU2018385766B2 (en) | 2017-12-15 | 2022-12-01 | Tarsus Pharmaceuticals, Inc. | Isoxazoline parasiticide formulations and methods for treating blepharitis |
| US12502377B2 (en) | 2019-04-04 | 2025-12-23 | Tarsus Pharmaceuticals, Inc. | Method of eradicating ticks that attach to humans using lotilaner formulations |
| WO2021018750A1 (en) | 2019-07-26 | 2021-02-04 | Proqr Therapeutics Ii B.V. | Ophthalmic compositions comprising viscosifying polymers and nucleic acids |
| WO2023140357A1 (ja) * | 2022-01-21 | 2023-07-27 | センジュ ユーエスエー、インコーポレイテッド | 水性液剤 |
| CN118978426B (zh) * | 2024-10-22 | 2025-05-16 | 浙江大学 | 一种甘油的酸化处理方法、酸化甘油及其应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5136014A (en) * | 1990-06-22 | 1992-08-04 | E. I. Du Pont De Nemours And Company | Hyperbranched polyesters |
| RO113612B1 (ro) * | 1991-04-17 | 1998-09-30 | Merck & Co Inc | Compozitie oftalmica |
| US6316443B1 (en) * | 1994-08-04 | 2001-11-13 | Merck & Co., Inc. | Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist |
| DE19726186A1 (de) * | 1997-06-20 | 1998-12-24 | Boehringer Ingelheim Int | Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen |
| FR2772771B1 (fr) * | 1997-12-19 | 2000-01-28 | Oreal | Utilisation de polymeres hyperbranches et de dendrimeres comportant un groupement particulier, en tant qu'agent filmogene, les compositions filmogenes les comprenant et leur utilisation notamment en cosmetique ou en pharmacie |
| WO2000063409A1 (en) | 1999-04-21 | 2000-10-26 | Massachusetts Institute Of Technology | Endosomolytic agents and cell delivery systems |
| US7030097B1 (en) | 1999-07-14 | 2006-04-18 | Cornell Research Foundation, Inc. | Controlled nucleic acid delivery systems |
| SK282717B6 (sk) | 2000-03-10 | 2002-11-06 | �Stav Experiment�Lnej Farmakol�Gie Sav | Spôsob prípravy ultravysokomolekulových hyalurónanov |
| WO2002026867A2 (en) | 2000-09-29 | 2002-04-04 | The Regents Of The University Of California | Dendrimeric support or carrier macromolecule |
| MXPA03007665A (es) | 2001-02-26 | 2004-03-16 | Univ Duke | Polimeros dendriticos novedosos y sus usos biomedicos. |
| DK1368054T3 (da) | 2001-03-08 | 2008-02-04 | Nymox Pharmaceutical Corp | Anvendelse af neurale trådproteiner til behandling af tumorer |
| FR2830450B1 (fr) | 2001-10-09 | 2004-02-06 | Univ Pasteur | Utilisation de dendrimeres dans une composition ophtalmique |
| AR038269A1 (es) | 2002-01-09 | 2005-01-12 | Novartis Ag | Articulos polimericos que tienen un recubrimiento lubrico, y metodo para fabricarlos |
| GB0209022D0 (en) | 2002-04-19 | 2002-05-29 | Imp College Innovations Ltd | Compounds |
| WO2004060283A2 (en) | 2002-12-16 | 2004-07-22 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
| MXPA05008579A (es) * | 2003-02-13 | 2007-11-21 | Nat Ct Scient Res Demokritos | Dendrimeros multifuncionales y polimeros hiperramificados como sistemas de distribucion de drogas y genes. |
| JP2005008614A (ja) | 2003-03-28 | 2005-01-13 | Nano Career Kk | 高分子ミセルを用いた眼科用ドラッグデリバリーシステム |
| US7109247B2 (en) | 2003-05-30 | 2006-09-19 | 3M Innovative Properties Company | Stabilized particle dispersions containing nanoparticles |
| US7189456B2 (en) | 2004-03-04 | 2007-03-13 | Transitions Optical, Inc. | Photochromic optical article |
| WO2006031358A2 (en) | 2004-08-13 | 2006-03-23 | Hyperbranch Medical Technology, Inc. | Dendritic polymers, crosslinked gels, and their uses as ophthalmic sealants and lenses |
| US20060057215A1 (en) * | 2004-09-15 | 2006-03-16 | Raiche Adrian T | Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility |
| US7837986B2 (en) | 2004-12-01 | 2010-11-23 | E. I. Du Pont De Nemours And Company | Protein-based polymer tissue adhesives for medical use |
| AR054227A1 (es) * | 2005-02-21 | 2007-06-13 | Basf Ag | Composicion de principios activos |
| US20060257359A1 (en) | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
| US8679536B2 (en) | 2005-08-24 | 2014-03-25 | Actamax Surgical Materials, Llc | Aldol-crosslinked polymeric hydrogel adhesives |
| US7666331B2 (en) | 2005-08-31 | 2010-02-23 | Transitions Optical, Inc. | Photochromic article |
| JP5989294B2 (ja) | 2006-01-20 | 2016-09-07 | スターファーマ・プロプライエタリー・リミテッドＳｔａｒｐｈａｒｍａ Ｐｔｙ Ｌｔｄ | 修飾高分子 |
| WO2008054466A2 (en) | 2006-03-03 | 2008-05-08 | Dendritic Nanotechnologies, Inc. | Delivery of biologically active materials using core-shell tecto (dendritic polymers) |
| US20080031916A1 (en) * | 2006-04-24 | 2008-02-07 | Heather Sheardown | Dendrimer cross-linked collagen |
| WO2008027340A2 (en) * | 2006-08-30 | 2008-03-06 | Merck & Co., Inc. | Topical ophthalmic formulations |
| WO2008030591A2 (en) | 2006-09-08 | 2008-03-13 | Dendritic Nanotechnologies, Inc. | Peham dendrimers as excipients |
| WO2008067127A2 (en) * | 2006-11-09 | 2008-06-05 | Alcon Research, Ltd. | Water insoluble polymer matrix for drug delivery |
| US7906214B2 (en) | 2007-01-26 | 2011-03-15 | Transitions Optical, Inc. | Optical elements comprising compatiblizing coatings and methods of making the same |
| PL2214646T3 (pl) * | 2007-10-05 | 2021-12-20 | Wayne State University | Dendrymery do przedłużonego uwalniania związków |
| EP2214731B1 (en) | 2007-11-14 | 2014-05-14 | Actamax Surgical Materials LLC | Oxidized cationic polysaccharide-based polymer tissue adhesive for medical use |
| US20100008993A1 (en) | 2008-07-14 | 2010-01-14 | Proksch Joel W | Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs |
| WO2010017184A2 (en) * | 2008-08-08 | 2010-02-11 | Virginia Commonwealth University | Dendrimer hydrogels |
-
2010
- 2010-05-05 US US12/774,419 patent/US8211450B2/en not_active Expired - Fee Related
-
2011
- 2011-05-04 JP JP2013509213A patent/JP2013528589A/ja active Pending
- 2011-05-04 CA CA2797123A patent/CA2797123A1/en not_active Abandoned
- 2011-05-04 EP EP20110778244 patent/EP2566487A4/en not_active Withdrawn
- 2011-05-04 US US13/695,930 patent/US20130053374A1/en not_active Abandoned
- 2011-05-04 KR KR1020127031915A patent/KR20130121685A/ko not_active Withdrawn
- 2011-05-04 WO PCT/US2011/035147 patent/WO2011140194A1/en not_active Ceased
- 2011-05-04 CN CN2011800332340A patent/CN103096901A/zh active Pending
- 2011-05-04 MX MX2012012846A patent/MX2012012846A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2566487A1 (en) | 2013-03-13 |
| JP2013528589A (ja) | 2013-07-11 |
| US8211450B2 (en) | 2012-07-03 |
| US20110275617A1 (en) | 2011-11-10 |
| US20130053374A1 (en) | 2013-02-28 |
| CN103096901A (zh) | 2013-05-08 |
| KR20130121685A (ko) | 2013-11-06 |
| MX2012012846A (es) | 2013-05-22 |
| WO2011140194A1 (en) | 2011-11-10 |
| EP2566487A4 (en) | 2014-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2797123A1 (en) | Ophthalmic composition | |
| El-Nabarawi et al. | Natamycin niosomes as a promising ocular nanosized delivery system with ketorolac tromethamine for dual effects for treatment of candida rabbit keratitis; in vitro/in vivo and histopathological studies | |
| JP2013528589A5 (enExample) | ||
| Wu et al. | Breaking barriers in eye treatment: polymeric nano-based drug-delivery system for anterior segment diseases and glaucoma | |
| Pandian et al. | RES‐loaded pegylated CS NPs: for efficient ocular delivery | |
| CA2737263C (en) | Mucomimetic compositions and uses therefore | |
| MX366099B (es) | Deposito de fosfolipidos. | |
| NZ599952A (en) | Ophthalmic emulsion | |
| CA2535364A1 (en) | Hyaluronic acid nanoparticles | |
| JP2014015453A (ja) | ソフトコンタクトレンズ用眼科組成物 | |
| CN101889974A (zh) | 一种壳聚糖避孕凝胶及其制备方法 | |
| Devi et al. | A novel approach of drug localization through development of polymeric micellar system containing azelastine HCl for ocular delivery | |
| JP2015042685A (ja) | シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| EP2578083B1 (fr) | Compositions désinfectantes et détergentes | |
| JP2003206241A5 (enExample) | ||
| JP2014015450A (ja) | 水性眼科組成物 | |
| JP5984531B2 (ja) | 水性眼科組成物 | |
| NZ608406A (en) | Use of storage stable viscous phospholipid depot to treat wounds | |
| JP2025065279A (ja) | ソフトコンタクトレンズ用眼科組成物 | |
| TW201107414A (en) | Ethyleneoxide butyleneoxide block copolymer compositions | |
| TW201722437A (zh) | 眼科組成物 | |
| AU2012245454A1 (en) | Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents | |
| JP2012532878A5 (enExample) | ||
| Jansook et al. | Development of Piperine/HPβCD-Loaded PVA-Coated iron oxide nanoparticles in in situ gel for enhanced retinal delivery and Anti-VEGF activity | |
| EP2800553A1 (en) | Methods and kits for extending contact lens use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20160504 |